Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
General BiologicalsROCO:4117 -9.96%50 Gross Margin % is 42.78% as of Dec. 2025, which is 5% below its 10-year median of 45.18. GuruFocus rates ROCO:4117 with a GF Score™ of 50/100 and a GF Value™ of NT$14.06 (Modestly Undervalued). The stock has 8 warning signs investors should review. Among 941 Drug Manufacturers companies, General Biologicals ranks worse than 83.42% on this metric.
General Biologicals Corp gross margin has been in long-term decline. The average rate of decline per year is -29.9%.
The historical rank and industry rank for General Biologicals's Gross Margin % or its related term are showing as below:
ROCO:4117'
s Gross Margin % Range Over the Past 10 Years
Min: 2.99 Med: 45.18 Max: 52.93
Current: 27.63
During the past 13 years, the highestGross Margin % of General Biologicals was 52.93%. The lowest was 2.99%. And the median was 45.18%.
ROCO:4117's Gross Margin % is ranked worse than 83.42% of 941
companies
in the Drug Manufacturers industry
Industry Median: 48.54
vs ROCO:4117: 27.63
General Biologicals had a gross margin of 42.78% for the quarter that ended in Dec. 2025 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for General Biologicals was -29.90% per year.
General Biologicals (ROCO:4117) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
General Biologicals had a gross margin of 42.78% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
General Biologicals Gross Margin % Related Terms
General Biologicals Gross Margin % Historical Data
* Premium members only.
The historical data trend for General Biologicals's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, General Biologicals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
General Biologicals Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, General Biologicals's Gross Margin % distribution charts can be found below:
* The bar in red indicates where General Biologicals's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
General Biologicals (ROCO:4117) has a Gross Margin % of 42.78% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on General Biologicals and its competitors. This is near median its historical median of 45.18. Over the past decade, General Biologicals' Gross Margin % has ranged from 2.99 to 52.93. According to the industry distribution chart, General Biologicals ranks #785 out of 941 companies in the Drug Manufacturers industry, placing it in the top 83.4%.
Is General Biologicals' Gross Margin % too high?
General Biologicals' current Gross Margin % of 42.78% is near median its 10-year median of 45.18. Over the past 10 years, this metric has ranged from a low of 2.99 to a high of 52.93. The Drug Manufacturers industry median Gross Margin % is 48.54. General Biologicals' value of 42.78% is 11.9% below this industry median. Based on the distribution chart, General Biologicals ranks #785 out of 941 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, General Biologicals has a GF Score™ of 50/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does General Biologicals' Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, General Biologicals ranks #785 out of 941 companies for Gross Margin %. This places General Biologicals in the lower half of its industry. The industry median Gross Margin % is 48.54. General Biologicals' value of 42.78% is 11.9% below this benchmark. Historically, General Biologicals' own Gross Margin % has ranged from 2.99 to 52.93 over the past decade. While the company's 10-year median is 45.18 vs. the industry median of 48.54, General Biologicals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 941 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. General Biologicals's current Gross Margin % of 42.78% is 11.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on General Biologicals and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. General Biologicals's current Gross Margin % is 42.78%, which is near median its own 10-year median of 45.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is General Biologicals stock overvalued right now?
Based on GuruFocus' analysis, General Biologicals (ROCO:4117) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$14.06, compared to a current price of NT$10.40 — trading 26% below its estimated fair value. The current Gross Margin % is 42.78%, which is near median its 10-year median of 45.18 and 11.9% below the Drug Manufacturers industry median of 48.54. General Biologicals' overall GF Score™ is 50/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For General Biologicals (ROCO:4117), the current Gross Margin % is 42.78% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is General Biologicals (ROCO:4117) Overvalued in 2026?
Based on GuruFocus' analysis, General Biologicals stock appears to be undervalued.
The current stock price of NT$10.40 is trading 26% below its estimated GF Value™ of NT$14.06.
GuruFocus considers General Biologicals to be Modestly Undervalued.
Key valuation signals for ROCO:4117:
Gross Margin %: 42.78% (near median its 10-year median of 45.18)
GF Value™: NT$14.06 vs. price of NT$10.40 (26% below fair value)
Industry Position: 11.9% below the Drug Manufacturers median (#785 of 941)
No single metric tells the full story. See the ROCO:4117 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
General Biologicals Corp is a developer and manufacturer of vitro diagnostic devices in Taiwan. It offers research development, marketing and servicing of products and solutions for hospitals, medical laboratories, blood banks, and research and industry. Its products include Anti-HDV, HIV Ag-Ab COMB, Anti-HBs, and many others.
50GF Score
Get the complete analysis for ROCO:4117
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4117 has been successfully added to your 
